View Older Stories View More Recent Stories

Apr 15, 2025 08:04AM Ensysce Biosciences (ENSC) Announces Positive Data from Opioid Overdose Protection Study
Apr 15, 2025 08:00AM Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
Mar 31, 2025 08:04AM Ensysce Biosciences (ENSC) Announces 315K Share Offering at $3.49/sh
Mar 31, 2025 08:00AM Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Mar 18, 2025 08:00AM Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
Mar 10, 2025 05:00PM Ensysce Biosciences (ENSC) Misses Q4 EPS by 290c
Mar 10, 2025 04:15PM Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Mar 5, 2025 08:00AM Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
Feb 5, 2025 08:05AM Ensysce Biosciences (ENSC) Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR
Feb 5, 2025 08:00AM Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment
Jan 22, 2025 08:01AM Ensysce Biosciences (ENSC) Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
Jan 22, 2025 08:00AM Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
Jan 8, 2025 08:03AM Ensysce Biosciences (ENSC) Issues Annual Shareholder Letter
Jan 8, 2025 08:00AM Ensysce Biosciences Issues Annual Shareholder Letter
Dec 23, 2024 08:00AM Ensysce Biosciences Regains Full Compliance with Nasdaq
Dec 10, 2024 08:00AM Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
Dec 4, 2024 08:04AM Ensysce Biosciences (ENSC) Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
Dec 4, 2024 08:00AM Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
Dec 3, 2024 04:17PM Ensysce Biosciences (ENSC) Announces 1:15 Reverse Share Split
Dec 3, 2024 04:15PM Ensysce Biosciences Announces 1-for-15 Reverse Stock Split
Nov 26, 2024 08:00AM Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
Nov 12, 2024 04:15PM Ensysce Biosciences Reports Third Quarter 2024 Financial Results
Nov 7, 2024 08:12AM Ensysce Biosciences (ENSC) Receives Positive Nasdaq Listing Determination
Nov 7, 2024 08:00AM Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Oct 8, 2024 08:00AM Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
Oct 2, 2024 08:08AM Ensysce Biosciences (ENSC) Provides Shareholder Update, Responds to Recent Shareholder Inquiries
Oct 2, 2024 08:00AM Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
Sep 27, 2024 04:35PM Ensysce Biosciences (ENSC) has not regained compliance, receives Nasdaq notice
Sep 27, 2024 04:30PM Ensysce Biosciences Receives Notice from Nasdaq
Sep 24, 2024 08:00AM Ensysce Biosciences Presenting at Upcoming Meetings
Sep 19, 2024 07:03AM Ensysce Biosciences (ENSC) Submits Phase 3 Protocol to the FDA
Sep 19, 2024 07:00AM Ensysce Biosciences Submits Phase 3 Protocol to the FDA
Sep 13, 2024 08:00AM Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
Aug 29, 2024 08:04AM Ensysce Biosciences (ENSC) Announces $5M Share and Warrant Placement at $.47/sh
Aug 29, 2024 08:00AM Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants
Aug 27, 2024 02:32PM Ensysce Biosciences (ENSC) Announces IRB Approval for Key MPAR Study
Aug 27, 2024 02:30PM Ensysce Biosciences Announces IRB Approval for Key MPAR Study
Aug 27, 2024 08:10AM Ensysce Biosciences (ENSC) Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection
Aug 27, 2024 08:00AM Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection
Aug 15, 2024 04:30PM Ensysce Biosciences (ENSC) Misses Q1 EPS by 22c
Aug 14, 2024 04:15PM Ensysce Biosciences Reports Second Quarter 2024 Financial Results
Aug 7, 2024 12:00AM Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium
Jul 23, 2024 10:34AM Ensysce Biosciences (ENSC) Issues Mid-Year 2024 Update
Jul 23, 2024 08:00AM Ensysce Biosciences Provides Mid-Year 2024 Update
Jul 9, 2024 08:00AM Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
Jun 27, 2024 08:00AM Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
Jun 25, 2024 08:05AM Ensysce Biosciences (ENSC) Announces Partnership to Scale and Manufacture New Drug Candidate
Jun 25, 2024 08:00AM Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
Jun 25, 2024 08:00AM Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
View More Recent Stories View Older Stories